TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:52
Accelerate Diagnostics Inc ( AXDX ) https://acceleratediagnostics.com
1.11USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-72.25%
AXDX
SPY
32.66%
-97.69%
AXDX
SPY
108.59%
-99.35%
AXDX
SPY
302.52%
-99.42%
AXDX
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
27.66
123.72
0.03
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.52
2.33
-0.57
-71.48
0.00
-3.57
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-289.68
28.77
-292.06
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
-0.7584
-135.81
-404.70
-1.38
Other Earnings and Cash Flow Stats:
Accelerate Diagnostics Inc ( AXDX ) Net Income TTM ($MM) is -53.46
Accelerate Diagnostics Inc ( AXDX ) Operating Income TTM ($MM) is -35.78
Accelerate Diagnostics Inc ( AXDX ) Owners' Earnings Annual ($MM) is -42.47
Accelerate Diagnostics Inc ( AXDX ) Current Price to Owners' Earnings ratio is -1.37
Accelerate Diagnostics Inc ( AXDX ) EBITDA TTM ($MM) is -34.48
Accelerate Diagnostics Inc ( AXDX ) EBITDA Margin is -292.06%
Capital Allocation:
Accelerate Diagnostics Inc ( AXDX ) has paid 0.00 dividends per share and bought back -10.362 million shares in the past 12 months
Accelerate Diagnostics Inc ( AXDX ) has increased its debt by 78.978 million USD in the last 12 months
Capital Structure:
Accelerate Diagnostics Inc ( AXDX ) Interest-bearing Debt ($MM) as of last quarter is 116
Accelerate Diagnostics Inc ( AXDX ) Annual Working Capital Investments ($MM) are -8
Accelerate Diagnostics Inc ( AXDX ) Book Value ($MM) as of last quarter is -49
Accelerate Diagnostics Inc ( AXDX ) Debt/Capital as of last quarter is -242%
Other Balance Sheet Stats:
Accelerate Diagnostics Inc ( AXDX ) has 19 million in cash on hand as of last quarter
Accelerate Diagnostics Inc ( AXDX ) has 18 million of liabilities due within 12 months, and long term debt 58 as of last quarter
Accelerate Diagnostics Inc ( AXDX ) has 24 common shares outstanding as of last quarter
Accelerate Diagnostics Inc ( AXDX ) has 0 million USD of preferred stock value
Academic Scores:
Accelerate Diagnostics Inc ( AXDX ) Altman Z-Score is -33.49 as of last quarter
Accelerate Diagnostics Inc ( AXDX ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Accelerate Diagnostics Inc ( AXDX ) largest shareholder is owning shares at 0.00 ($MM) value
PATIENCE JOHN(an insider) Bought 200000 shares of Accelerate Diagnostics Inc ( AXDX ) for the amount of $314000.00 on 2024-12-03
40.61% of Accelerate Diagnostics Inc ( AXDX ) is held by insiders, and 17.45% is held by institutions
Accelerate Diagnostics Inc ( AXDX ) went public on 1996-11-18
Other Accelerate Diagnostics Inc ( AXDX ) financial metrics:
FCF:-28.02
Unlevered Free Cash Flow:-58.39
EPS:-2.35
Operating Margin:-289.68
Gross Profit Margin:28.77
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:120.78
Beta:-1.38
Buffet's Owners Earnings:-42.47
Price to Owner's Earnings:-1.37
About Accelerate Diagnostics Inc ( AXDX ) :
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.